Imunon, Inc. (IMNN) News
Follow Imunon, Inc. (IMNN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
IMUNON Agrees to Sell ThermoDox Rights for Equity, Milestones and Royalties
IMUNON will receive approximately 4.76% equity in VoxelDox, up to $16.5 million in milestones and 3.5%–6% royalties. Closing depends on VoxelDox completing a planned $2.5 million financing.
MNA | Oct 21, 2026, 12:24 PM UTC
M
Imunon Agrees to Sell ThermoDox Assets to VoxelDox
Imunon entered an asset purchase agreement to sell its ThermoDox assets to VoxelDox. Closing depends on VoxelDox raising at least $2.5 million; Imunon would receive a 4.76% fully diluted stake and up to $16.5 million in
MNA | Oct 21, 2026, 12:23 PM UTC
L
Imunon Swaps $1.2 Million of A-1 Note for Series B Preferred With Streeterville
Imunon entered into an Exchange Agreement with Streeterville Capital to retire $1.2 million of principal, plus accrued interest, under its Secured Promissory Note A-1. In return, the investor received 120 shares of newly
EQUITY | Sep 29, 2026, 12:03 PM UTC
L
IMUNON, Inc. (IMNN) Cites 14.7-Month OS Signal; Phase 3 Advancing
IMUNON reported a 14.7-month median OS difference (45.1 vs 30.4 months) in its 112-patient Phase 2 OVATION 2 study and said its pivotal Phase 3 OVATION 3 is enrolling, with two pre-planned interim OS analyses that could
NEWS | Sep 24, 2026, 12:12 PM UTC
L
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026 R&D Day presentation highlights include:LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. NASDAQ:IMNN, a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is pres
NEWS | Sep 24, 2026, 12:12 PM UTC
L
IMNN - IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
IMNN - IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
NEWS | Sep 24, 2026, 12:05 PM UTC
M
IMUNON IDMC recommends continuing Phase 2 MRD study unchanged
IMUNON said its independent monitoring committee recommended its Phase 2 MRD study of IMNN-001 continue without changes after reviewing safety data, citing no cytokine release syndrome, systemic toxicities, or serious im
EQUITY | Sep 22, 2026, 12:12 PM UTC
M
IMUNON Data Monitoring Committee backs continued Phase 2 IMNN-001
IMUNON says its Independent Data Monitoring Committee recommends continuing the Phase 2 MRD study without modification after reviewing safety data to date. It reports no cytokine release syndrome, systemic toxicities, or
EQUITY | Sep 22, 2026, 12:11 PM UTC
L
IMNN - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
IMNN - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
NEWS | Sep 22, 2026, 12:05 PM UTC
L
Imunon enters CRADA with NCI to advance IMNN-001 development
Imunon will work with the NCI Cancer Therapy Evaluation Program to evaluate IMNN-001 in new indications and combination regimens. Imunon retains ownership of its background intellectual property and can expand its IP thr
MNA | Sep 10, 2026, 01:32 PM UTC
L
IMUNON enters CRADA with National Cancer Institute for IMNN-001
IMUNON said it entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to advance clinical development of IMNN-001.
EQUITY | Sep 10, 2026, 01:30 PM UTC
L
IMNN-IMUNON sets agenda and speaker lineup for 2026 R&D Day
IMNN-IMUNON announced the full agenda and speaker lineup ahead of 2026 R&D Day, highlighting IMNN-001 clinical progress.
EQUITY | Sep 09, 2026, 12:32 PM UTC
L
IMNN announces 2026 R&D Day highlighting Phase 3 OVATION 3
IMUNON says it will host a 2026 R&D Day featuring Phase 3 OVATION 3 and the clinical potential of IMNN-001.
EQUITY | Aug 26, 2026, 12:30 PM UTC
L
IMNN - IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 - Click For Rele
IMNN - IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
EARNINGS | Aug 04, 2026, 12:00 PM UTC
H
IMNN Reports Strong Enrollment Momentum
IMNN sees strong enrollment in phase 3 trial
EQUITY | Jul 30, 2026, 01:00 PM UTC
L
IMNN Imunon reports positive phase 2 mrd clinical data for imnn-001, demonstrating the successful overcoming of historical il-12 safety barr
IMNN Imunon reports positive phase 2 mrd clinical data for imnn-001, demonstrating the successful overcoming of historical il-12 safety barriers in frontline ovarian cancer Imunon - imnn-001 demonstrates lower mrd rate,
EQUITY | Jul 21, 2026, 01:01 PM UTC
L
Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026
On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026 (
EQUITY | Jun 30, 2026, 08:44 PM UTC
M
IMNN Continues Phase 3 Study
IMUNON's Data Monitoring Committee recommends continuation of Phase 3 OVATION 3 Study without modification
EARNINGS | Jun 23, 2026, 12:02 PM UTC